Twist mediates suppression of inflammation by type I IFNs and Axl by Sharif, M. Nusrat et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
ARTICLE
JEM © The Rockefeller University Press  $8.00
Vol. 203, No. 8,  August 7, 2006  1891–1901  www.jem.org/cgi/doi/10.1084/jem.20051725
1891
Type I IFNs, IFNα and IFNβ, are pleiotropic 
cytokines that are induced in many cell types 
by viral or bacterial products (such as double-
stranded RNA and LPS) and have potent anti-
viral eff  ects (1). In addition to antiviral eff  ects, 
type I IFNs exhibit immunomodulatory prop-
erties and enhance innate and acquired immune 
responses, promote the transition from innate to 
acquired immunity, and promote certain auto-
immune disorders (1–5). Mechanisms by which 
type I IFNs enhance immunity include stimula-
tion of cytokine and chemokine production, 
activation of NK cells, maturation of DCs, and 
promoting Th1 responses and increased B cell 
class switching and antibody production.
Like most cytokines, type I IFNs are plei-
otropic and also have suppressive eff  ects  on 
immunity and infl  ammation. The suppressive 
eff   ects of type I IFNs can predominate in 
  certain (patho)physiological settings. For ex-
ample, type I IFNs suppress delayed type hy-
persensitivity reactions, host defense to Listeria 
monocytogenes and Mycobacteria  tuberculosis, 
and can suppress endotoxin-induced mortality 
under certain conditions (6–11). Type I IFNs 
suppress infl   ammation and disease activity 
in experimental allergic encephalitis, arthritis, 
colitis, and osteolysis (6, 12–15), and are eff  ec-
tive in the treatment of multiple sclerosis and 
possibly ulcerative colitis (16, 17). The mecha-
nisms underlying the suppressive eff  ects  of 
type I IFNs are not well understood but include 
suppression of cell proliferation, IL-12 and 
TNFα production, and, under specifi  c condi-
tions, IFNγ production (5). IFN-induced sup-
pression of TNFα production was required for 
the suppressive eff  ects of type I IFNs in experi-
mental allergic encephalitis, and treatment with 
type I IFNs suppressed TNFα production in 
vivo in humans (15, 18). Thus, IFN-mediated 
suppression of TNFα production is important 
in disease pathophysiology, but mechanisms by 
which type I IFNs suppress TNFα production 
and infl  ammation have not been clarifi  ed.
TNFα is a potent infl  ammatory cytokine 
that is important for host defense and is ex-
pressed at sites of infl  ammation where it acti-
vates resident tissue cells, infi  ltrating immune 
cells and endothelial cells in surrounding blood 
vessels (19). TNFα has been implicated in the 
pathogenesis of many acute and chronic in-
fl  ammatory conditions, including septic shock, 
rheumatoid arthritis, and infl  ammatory bowel 
disease. TNFα also appears to play a role in 
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promoting end organ infl  ammation, such as nephritis, in sys-
temic lupus erythematosus (SLE), although TNFα suppresses 
the development of autoimmunity in murine models of 
this disease (4, 20). Major sources of TNFα are activated 
macrophages and DCs, and major inducers of TNF include 
pathogen-associated molecular patterns (such as TLR ligands), 
infl  ammatory cytokines (such as IL-1), cell surface and se-
creted factors expressed by activated T cells, and immune 
complexes that activate cells via Fc receptors. Fc receptors are 
key mediators of TNF production in acute models of im-
mune complex-induced infl  ammation, including the Arthus 
reaction and experimental arthritis, and likely contribute to 
TNFα production in chronic infl  ammatory diseases such as 
rheumatoid arthritis and SLE (21).
TNFα production needs to be tightly controlled to avoid 
excessive infl  ammation, tissue damage, and toxicity. NF-κB 
is an important inducer of TNFα transcription, and activa-
tion of the p38 mitogen-activated protein kinase (MAPK) is 
required for stabilization and effi   cient translation of TNFα 
mRNA (19). Major immunosuppressive and antiinfl  amma-
tory factors, such as IL-10 and corticosteroids, suppress TNFα 
production by inhibiting activation of NF-κB and p38. How 
antiinfl   ammatory factors suppress NF-κB activation is not 
well understood and mechanisms that suppress activation of 
IκB kinases, degradation of I-κB, and nuclear translocation 
of NF-κB subunits are under intense investigation. Recent 
work has identifi  ed an alternative mechanism of inhibiting 
NF-κB function, namely inhibition of p65/RelA-mediated 
transactivation in the nucleus by Twist proteins (22). Twist 
proteins (Twist1 and Twist2) are basic helix loop helix 
(bHLH) transcriptional repressors that bind to E boxes in 
gene promoters, including the TNFα promoter, and repress 
transcription. Twist proteins are key regulators of NF-κB–
mediated infl  ammation, as Twist2 defi  ciency, or haploinsuf-
fi  ciency of Twist1 and Twist2, results in a lethal systemic 
infl   ammatory syndrome linked to enhanced proinfl  amma-
tory cytokine production (22). TNFα production is also sup-
pressed by receptor tyrosine kinases of the Tyro 3 family, 
which is comprised of Tyro 3, Mer, and Axl (23). Tyro 3 
family kinases contribute to the antiinfl  ammatory eff  ects of 
apoptotic cell phagocytosis and suppress TNFα production 
by unknown mechanisms (23–26). In this study, we investi-
gated mechanisms by which type I IFNs suppress immune 
complex/Fc receptor-induced TNFα production, which is 
relevant for the modulation of chronic infl  ammation by IFNs. 
We found that IFNα suppressed TNFα production by in-
ducing a cascade of gene activation that resulted in repression 
of the TNFα promoter by Twist.
RESULTS
IFN𝗂 suppresses Fc𝗄R- and TLR-induced TNF𝗂 production
We determined the eff  ects of preculture with IFNα on FcγR-
induced production of TNFα. Primary human macrophages 
were cultured for 2 d with low priming concentrations 
(250 pg/ml = 100 antiviral U/ml) or saturating concentra-
tions (7.5 ng/ml = 3,000 U/ml) of IFNα, stimulated by 
cross-linking of FcγRs, and TNFα production was measured. 
As expected, cross-linking of FcγRs on control macrophages 
resulted in the secretion of substantial levels of TNFα (Fig. 
1 A). In contrast, preculture with IFNα dramatically sup-
pressed FcγR-induced secretion of TNFα protein (Fig. 1 A). 
In addition, IFNα strongly suppressed FcγR-induced increases 
in TNFα mRNA expression (Fig. 1 B). Inhibition of FcγR-
induced TNFα production by IFNα was highly reproducible 
Figure 1.  IFN𝗂 suppresses Fc𝗄R-induced TNF𝗂 production. Macro-
phages were cultured for 2 d without IFNs or with IFNα (A and B) or IFNγ 
(D). FcγRs were then cross-linked using plate bound IgG (20 μg/ml). In A 
and D, supernatants were harvested 16 h later, and TNFα was measured 
using ELISA. In B, cells were harvested 60 and 90 min after FcγR cross-
linking, and TNFα mRNA levels measured using real-time PCR. For IFNα, 
100 antiviral U/ml = 250 pg/ml and 3,000 U/ml = 7.5 ng/ml; for IFNγ, 
100 U/ml = 10 ng/ml. (C) Groups of three to four mice were injected i.p. 
with PBS or 105 U of IFNα, and 2 d later they were injected i.v. with 300 
μg (100 μl) of immune complexes formed by mixing rabbit anti–human 
F(ab′) with human IgG. Serum was obtained 1 h later, and TNFα was mea-
sured using ELISA. Results from three independent experiments are shown.JEM VOL. 203, August 7, 2006  1893
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and has been observed in experiments with more than 20 dif-
ferent blood donors. IFNα also eff  ectively inhibited immune 
complex-induced TNFα production in vivo (Fig. 1 C). In 
contrast to the eff  ects of IFNα, preculture of macrophages 
with IFNγ resulted in increased TNFα production after FcγR 
ligation (as expected) (Fig. 1 D), thus demonstrating the spec-
ifi  city of IFNα-  mediated inhibition.
We then investigated whether IFNα suppressed the 
  production of cytokines other than TNFα and the eff  ects 
of IFNα on the activation of macrophages by TLR ligands. 
In addition to suppressing TNFα production (Fig. 1), IFNα 
eff  ectively suppressed FcγR-mediated induction of CCL3/
MIP-1α, IL-8, and COX2, proinfl  ammatory factors whose 
induction is NF-κB dependent (similar to TNFα) (Fig. 2 A). 
FcγR cross-linking did not induce IL-12 expression in our 
system, and no additional eff   ects of IFNα were observed 
  (unpublished data). Similar to the strong and highly repro-
ducible inhibition of FcγR-induced cytokine expression, IFNα 
eff   ectively suppressed TLR2-induced cytokine production 
(Fig. 2 B, left and middle; n = 4). In contrast, suppression of 
TLR4-induced TNFα expression was relatively weak (20–
35%) and variable among diff  erent blood donors, even when 
low concentrations of LPS (0.1 ng/ml) were used (Fig. 2 B, 
right; n = 12). However, the partial suppression of LPS-
  induced TNFα production was statistically signifi  cant (P ≤ 
0.02 for all concentrations of LPS and IFNα that were used, 
paired Student t test; Fig. 2 B). These results demonstrate that 
IFNα suppressed the activation of macrophages by several 
key infl  ammatory stimuli. The weak suppression of low con-
centrations of LPS (Fig. 2 B), in contrast to the strong sup-
pression of FcγR-mediated eff  ects (Fig. 1), suggested that 
low levels of LPS contamination of immune complexes did 
not contribute to eff  ects observed in Fig. 1. The issue of LPS 
contamination of immune complexes was further addressed 
using C3H/HeJ mice that express a mutated nonfunctional 
TLR4. FcγR-mediated induction of TNFα production was 
comparable in macrophages from C3H/HeJ and genetically 
matched control C3H/OuJ mice, and was comparably sup-
pressed by IFNα (Fig. 2 C), thus indicating contaminating 
endotoxin did not contribute signifi  cantly to the regulation 
of TNFα production by immune complexes and IFNα.
IFN𝗂 effects on Fc𝗄R expression and proximal signaling
We investigated whether IFNα suppressed FcγR-induced 
TNFα production by down-regulating FcγR expression or 
signal transduction. Cell surface expression of the three 
Figure 2.  Suppression of Fc𝗄R-, TLR2-, and TLR4-induced cyto-
kine expression by IFN𝗂. (A) Human macrophages were cultured for 2 d 
with or without IFNα, FcγRs were cross-linked for 90 min using plate-
bound IgG (20 μg/ml), and mRNA levels were measured using real-time 
PCR and normalized relative to GAPDH. (B) Cells were stimulated over-
night with the TLR2 ligand Pam3Cys (100 ng/ml) or the TLR4 ligand LPS 
(1 ng/ml or 0.1 ng/ml), and culture supernatants were analyzed using ELISA. 
For experiments using Pam3Cys, a representative experiment out of four is 
shown. For LPS experiments, cumulative data is depicted (for 1 ng/ml LPS, 
n = 12; for 0.1 ng/ml LPS, n = 8). Differences were statistically signifi  -
cant (Students paired t test) at both concentrations of IFNα and both 
concentrations of LPS as marked. (C) Murine bone marrow–derived macro-
phages from C3H/HeJ mice that harbor a loss of function TLR4 mutation 
and from control C3H/OuJ mice were used.1894  TWIST AND AXL MEDIATE TYPE I IFN RESPONSES | Sharif et al.
FcγRs that are expressed on macrophages, FcγRI (CD64), 
FcγRII (CD32), and FcγRIII (CD16), was analyzed using 
fl  ow cytometry. Consistent with previous reports (21), IFNα 
had only modest eff  ects on cell surface FcγR expression (Fig. 
3 A). These results indicate that the inhibition of FcγR-
  induced TNFα production was not secondary to global sup-
pression of FcγR expression. Ligation of FcγRs activates 
NF-κB and MAPK pathways that are important for TNFα 
production (19). We assessed the eff  ects of IFNα on FcγR-
activated signal transduction by analyzing activation of NF-
κB and the extracellular signal–regulated kinase (ERK) family 
of MAPKs. The activation of ERKs by FcγR ligation was 
comparable in control and IFNα-treated macrophages at 
each time point tested (Fig. 3 B). These results indicate that 
IFNα did not globally block FcγR signal transduction and 
are consistent with comparable cell surface FcγR expression 
in control and IFN-treated cells (Fig. 3 A). Activation of the 
NF-κB pathway was assessed by measuring phosphorylation 
and degradation of I-κB at several time points after FcγR 
  ligation of control and IFNα-primed macrophages. I-κB 
phosphorylation and degradation after FcγR ligation were 
modest (Fig. 3 C) relative to an LPS-positive control (unpub-
lished data), and both phosphorylation and degradation of 
I-κB were partially suppressed in IFNα-treated cells relative 
to control cells (Fig. 3 C, a representative experiment out of 
three is shown). The modest suppressive eff  ect of IFNα on 
NF-κB activation is consistent with previous results in a 
  diff  erent system (27) but is unlikely to explain the strong sup-
pression of TNFα production that was observed in IFNα-
treated cells (Fig. 1, A and B). Therefore, we investigated 
additional IFNα-inducible mechanisms that may inhibit 
TNFα production.
Twist proteins mediate IFN𝗂 suppression 
of TNF𝗂 production
We reasoned that IFNα induced the expression of inhibitors 
of NF-κB activation or function and tested several candidate 
inhibitors, including Twist proteins (22). Twist1 and Twist2 
are bHLH transcriptional repressors that bind to an E-box 
in the TNFα promoter and repress TNFα transcription by 
inhibiting transcriptional activation by the p65 subunit of 
NF-κB (22). We fi  rst tested if Twist expression was induced 
by IFNα. Interestingly, Twist1 and Twist2 mRNA expression 
was strongly induced by IFNα (Fig. 4, A and B). The kinetics 
Figure 3.  IFN𝗂 regulation of Fc𝗄R expression and signaling. (A) Flow 
cytometry was used to measure cell surface FcγR expression on control 
and IFNα-treated macrophages. IFNα was used at 3,000 U/ml, and similar 
results were obtained over a range of IFNα concentrations from 100 U/ml 
to 3,000 U/ml. (B) Macrophages were cultured for 2 d with 3,000 U/ml 
of IFNα, FcγRs were cross-linked using plate-bound IgG (20 μg/ml), and 
activation of ERKs was measured using immunoblotting. (C) Control mac-
rophages or cells cultured for 2 d with IFNα (3,000 U/ml) were added 
to control or IgG-coated (20 μg/ml) wells. Cell extracts were   analyzed by 
immunoblotting of replicate fi  lters.
Figure 4.  IFN𝗂 induces expression of Twist. (A and B) Twist1 and 
Twist2 mRNA levels were measured in control and IFNα-primed macro-
phages using real-time PCR and were normalized relative to GAPDH 
levels. (C) Twist2 expression was measured using immunoblotting. 
(D) Nuclear extracts from control and IFNα-stimulated cells were used in 
an EMSA assay with a radiolabeled E box containing oligonucleotide. 
Control and Twist antibodies (2 μg) were added to the binding reaction 
20 min before adding radiolabeled oligonucleotide.JEM VOL. 203, August 7, 2006  1895
ARTICLE
of Twist induction were delayed such that elevated Twist 
expression was observed after 2 d of IFNα stimulation, which 
corresponds to the time point when TNFα expression was 
suppressed. Twist protein levels increased in parallel with 
mRNA levels (Fig. 4 C). Interestingly, treatment with IFNα 
for 2 d induced higher Twist expression than did treatment 
with TNFα for 3 h, which was previously shown to rapidly 
induce Twist expression in a feedback inhibition loop (22) 
and was used as a positive control (Fig. 4 C, compare lane 2 
to lanes 4 and 6). We then used gel shift assays to investi-
gate whether IFNα-induced Twist proteins bind to DNA. 
Twist bHLH transcription factors bind to promoter elements 
termed E boxes and have been shown to bind to an E box–
containing oligonucleotide derived from the TNFα pro-
moter (22). IFNα induced a nuclear DNA-binding complex 
that bound to an E box–containing oligonucleotide derived 
from the TNFα promoter (Fig. 4 D), consistent with previ-
ously reported results (22). Similar results were obtained us-
ing a consensus E-box oligonucleotide (unpublished data). 
Formation of this IFNα-inducible DNA-binding complex 
was disrupted by Twist antibodies but not by control anti-
bodies, indicating that this complex contained Twist proteins 
(Fig. 4 D). Collectively, the results establish that IFNα in-
duces the expression of Twist proteins.
Next, we used macrophages from Twist-defi  cient mice 
to determine the role of Twist in the regulation of TNFα 
production by IFNα. Twist1 defi  ciency is embryonal lethal, 
whereas twist2−/− and twist1+/− twist2+/− mice develop a 
  severe spontaneous neonatal infl  ammatory syndrome (22, 28). 
twist1−/− macrophages were not available, and therefore we 
used bone marrow–derived macrophages from twist2−/− and 
twist1+/− twist2+/− mice and genetically matched controls. 
Macrophages were cultured with or without IFNα for 2 d, 
plated onto control or IgG-coated wells, and TNFα protein 
and mRNA levels were measured using ELISA and qPCR. 
As observed previously with human macrophages (Fig. 1), 
IFNα suppressed FcγR-mediated induction of TNFα pro-
tein and mRNA in wild-type murine macrophages (Fig. 5, 
A and B). In contrast, in twist2−/− macrophages, IFNα was 
unable to suppress FcγR induction of TNFα protein (Fig. 5 A) 
or mRNA (Fig. 5 B). Comparable results were obtained when 
twist1+/− twist2+/− macrophages were used (Fig. 5, C and D). 
These results demonstrate that Twist transcriptional repres-
sors are required for IFNα suppression of FcγR-  induced 
TNFα production, and suggest that suppression is mediated 
by binding of Twist to the TNFα promoter.
We performed transient transfection and chromatin im-
munoprecipitation (ChIP) assays to gain greater insight into 
the regulation of the TNFα promoter by Twist proteins. 
RAW267.4 macrophage cells were cotransfected with a re-
porter construct driven by the TNFα promoter and increas-
ing amounts of Twist1 and Twist2, and FcγRs were ligated 
and reporter gene activity measured. Twist1 and Twist2 
  suppressed TNFα promoter activity in a dose-dependent 
Figure 5.  Twist mediates IFN𝗂 inhibition of Fc𝗄R-induced TNF 
production. (A and B) Bone marrow–derived macrophages from geneti-
cally matched control mice and twist2−/− mice were cultured with or 
without IFNα for 2 d and plated onto control or IgG-coated wells for 6 h 
(A) or 1 h (B). TNFα in culture supernatants was measured using ELISA (A), 
and TNFα mRNA levels were determined using real-time PCR and nor-
malized relative to GAPDH (B). (C and D) Macrophages from genetically 
matched control mice and twist1+/−twist2−/− mice were treated 
as in A and B, and TNFα protein and mRNA were measured.1896  TWIST AND AXL MEDIATE TYPE I IFN RESPONSES | Sharif et al.
manner (Fig. 6 A). Furthermore, TNFα promoter activity 
was eff  ectively suppressed by the combination of Twist1 and 
Twist2, consistent with the abrogation of IFNα eff  ects in 
compound heterozygote macrophages (Figs. 5, C and D). 
When a reporter construct harboring mutations in two out of 
the three E box motifs in the TNFα promoter was used, sup-
pression of TNFα promoter activity by Twist proteins was 
attenuated (Fig. 6 B), thereby suggesting that suppression of 
TNFα expression by Twist is dependent on its interaction 
with the TNFα promoter E boxes. Twist and NF-κB p65 
have been shown to interact when overexpressed in COS 
cells, but an association between these proteins was not de-
tected in primary macrophages (unpublished data), possibly 
because of lower expression. Next, we determined whether 
Twist proteins induced by IFNα bind to the endogenous 
TNFα promoter. ChIP assays demonstrated that IFNα in-
duced the binding of Twist to a TNFα promoter fragment 
that contains an E box (22) (Fig. 6 C). Negative controls in-
cluded lack of Twist binding to GAS sites (Fig. 6 C) and lack 
of Stat1 binding to E box sites (unpublished data). Collec-
tively, these results show that IFNα suppression of TNFα 
expression is mediated, at least in part, by induction of Twist 
binding to the TNFα promoter.
IFN𝗂 induction of Twist is mediated by the Axl 
tyrosine kinase
The delayed kinetics of Twist induction by IFNα (Fig. 4) 
suggested indirect activation of Twist by IFNα-induced 
  intermediates. To identify such intermediates we performed 
microarray analysis of IFNα-induced gene expression to 
screen for induction of genes known to regulate the expres-
sion of TNF or Twist. IFNα induced expression of the Axl 
member of the Tyro 3 family of receptor tyrosine kinases 
that are preferentially expressed in myeloid, neuronal, and 
reproductive system cells (23; unpublished data). Tyro 3 recep-
tor kinases have been implicated in suppression of TNFα 
production by unknown mechanisms (24), and their ligands 
protein S (29, 30) and apoptotic macrophages (25, 26) are 
constitutively present in our system, and expression of the 
Axl ligand Gas6 was induced by IFNα (unpublished data). 
Therefore, we tested whether IFNα-induced Axl expression 
contributed to IFNα-mediated induction of Twist and 
thereby suppression of TNFα production. First, we used 
qPCR to confi  rm the microarray results that IFNα, but not 
IL-10, induced Axl expression in macrophages (Fig. 7 A). 
Then, we investigated the role of Axl in mediating Twist 
expression by blocking the interaction of Axl with endoge-
nous ligands present in our cultures. Blocking of the interac-
tion of Axl with endogenous ligands using either soluble 
Axl-Fc or neutralizing anti-Axl antibodies eff  ectively sup-
pressed IFNα-induced Twist expression (Fig. 7 B), thereby 
implicating Axl in the induction of Twist expression. We 
then tested the eff  ects of stimulating Axl and related kinases 
in control macrophages that expressed low levels of Axl and 
related Tyro 3 family receptors. The Tyro 3 family receptor 
ligands protein S and Gas6, and also apoptotic cells that are 
bound by protein S and Gas6, induced expression of Twist1 
(Fig. 7 C), thus further supporting a role for Tyro 3 kinases 
in inducing Twist expression. Induction of Twist2 by Tyro 3 
receptor ligands in non-IFNα– treated macrophages was less 
robust (unpublished data), suggesting that induction of 
Twist2 is specifi  cally mediated by Axl or requires additional 
IFNα-inducible factors. To test the role of Axl in mediating 
IFNα suppression of TNFα expression, we measured the ef-
fects of blocking Axl interaction with endogenous ligands 
on FcγR-induced TNFα production. Consistent with the 
down-regulation of Twist expression when Axl function was 
blocked (Fig. 7 B), Axl blockade also reversed IFNα-
  mediated suppression of TNFα production (Fig. 7 D). 
Although IFNα induction of Axl expression in murine bone 
Figure 6.  Twist represses TNF𝗂 gene expression. (A) RAW267.4 macro-
phage cells were transfected in duplicate with a TNFα promoter-driven 
luciferase reporter construct, increasing amounts of Twist1 and Twist2 
expression vectors, and a Renilla luciferase-encoding internal control 
plasmid. Cells were stimulated by FcγR ligation for 4 h, and luciferase 
activity was measured and normalized relative to Renilla luciferase. A rep-
resentative experiment out of fi  ve is shown. (B) Transfection experiments 
were performed as in A, except a TNFα reporter construct in which 2 E 
boxes had been mutated was used. (C) Soluble chromatin was prepared 
from IFNα-treated primary macrophages and immunoprecipitated with 
control or anti-Twist antibodies. Extracted DNA was amplifi  ed using 
  primers that span the E box of the TNFα gene or the GAS site of the 
IRF-1 gene promoter.JEM VOL. 203, August 7, 2006  1897
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marrow–derived macrophages was more modest than in hu-
man monocyte-derived macrophages (unpublished data), a 
substantial role for Axl in mediating IFNα suppression of 
TNFα production was confi  rmed using axl−/− murine mac-
rophages (Fig. 7 E). Collectively, the results demonstrate that 
IFNα suppresses TNFα production by increasing macro-
phage expression of Axl and responsiveness to Axl ligands, 
thereby inducing Twist expression and Twist-mediated re-
pression of the TNFα promoter.
DISCUSSION
The antiinfl  ammatory eff  ects of type I IFNs are important 
for suppression of disease activity in several animal models 
of autoimmune disease and for the therapeutic effi   cacy of 
IFNs in multiple sclerosis, but mechanisms underlying their 
antiinfl  ammatory activity are poorly understood. In this 
study, we have identifi  ed a mechanism by which type I 
IFNs suppress production of the potent infl  ammatory cyto-
kine TNFα. Inhibition is mediated by induction of the re-
ceptor tyrosine kinase Axl, and activation of Axl leads to 
expression of Twist transcriptional repressors that suppress 
TNFα expression (Fig. 8). These results extend our under-
standing of the regulation of Twist proteins and their role 
in modulating cytokine production and provide insight into 
mechanisms that mediate the antiinfl   ammatory action of 
the Tyro 3 family of receptor tyrosine kinases. Manipulation 
of Axl expression and downstream activation of Twist rep-
resent a new approach to regulating cytokine production 
and infl  ammation.
An important mechanism of type I IFN action is regula-
tion of cellular responses to other extracellular factors (31). 
In the current paradigm, type I IFNs sensitize cells to 
Figure 7.  IFN𝗂-induced Axl mediates induction of Twist 
  expression. (A) Macrophages were stimulated for 1 or 2 d with IFNα 
(3,000 U/ml) or IL-10 (100 ng/ml), and Axl mRNA was measured using 
real-time PCR. (B) Macrophages were cultured for 2 d with IFNα 
(3,000 U/ml) in the presence of isotype control or anti-Axl antibodies 
(20 μg/ml) or with Axl-Fc (20 μg/ml), and Twist2 was measured using 
immunoblotting. (C) Macrophages were transferred into serum-free 
media for 6 h and then stimulated for 3 h with protein S (40 μg/ml), 
Gas6 (5 μg/ml), or apoptotic Jurkat cells (ratio of apoptotic cells to mac-
rophages of 10:1), and Twist1 mRNA was measured using real-time PCR. 
Twist1 mRNA was normalized relative to GAPDH (protein S and Gas6 
stimulations) or CD14 (apoptotic Jurkat stimulation). (D) Macrophages 
were cultured for 2 d with IFNα (3,000 U/ml) in the presence of isotype 
control or anti-Axl antibodies (20 μg/ml) or with Axl-Fc (20 μg/ml), 
FcγRs were cross-linked, and TNFα production was measured using 
ELISA. (E) Bone marrow–derived macrophages from genetically matched 
control mice and axl−/− mice were cultured with or without IFNα for 2 d, 
plated onto control or IgG-coated wells for 3 h, and TNFα mRNA levels 
were determined using real-time PCR and normalized relative to GAPDH. 
A representative experiment out of three is shown; similar results were 
obtained in a fourth experiment using macrophages triply defi  cient in 
Axl, Mer, and Tyro 3.1898  TWIST AND AXL MEDIATE TYPE I IFN RESPONSES | Sharif et al.
  activation by infl   ammatory cytokines and viruses, a phe-
nomenon that has been termed priming (31–36). Several 
mechanisms of priming have been described, including in-
creased expression of activating receptors, such as Toll-like 
receptor 3, that senses dsRNA and thereby viral infection 
(37). We show that type I IFNs also enhance cellular re-
sponses to antiinfl  ammatory factors, in this case protein S, 
Gas6, and apoptotic cells, by inducing expression of their 
receptor Axl. Thus, cells that have been primed by type I 
IFNs are not necessarily programmed for activation, but 
their fate and activation status are determined by the balance 
of pro- and antiinfl  ammatory factors present in the micro-
environment. Type I IFN-induced enhanced responsiveness 
to both pro- and antiinfl  ammatory factors extends our un-
derstanding of the concept of priming and helps explain the 
pleiotropic nature and homeostatic functions of type I IFNs. 
In contrast, the sole type II IFN, IFNγ, does not increase 
expression of inhibitory receptors (unpublished data) and 
subsumes a predominantly activating role.
Axl was the only member of the Tyro 3 family that was 
induced by IFNα. The Tyro 3 kinases are preferentially ex-
pressed in myeloid, neuronal, and reproductive system cells, 
and all three kinases are constitutively expressed in macro-
phages in our system (unpublished data). Since all three re-
ceptor kinases in this family share ligands, such as protein S, 
Gas6, and apoptotic cells, it is likely that Mer and Tyro 3 
contribute to the induction of Twist expression in control 
non-IFN–treated macrophages that were stimulated with 
these ligands (Fig. 8). Twist1 was induced more eff  ectively 
than Twist2 by Tyro 3 receptor ligands in control macro-
phages. As Axl expression increased after IFNα stimulation, 
Axl subsumed a major role in mediating the induction of 
Twist proteins, and both Twist1 and Twist2 were strongly 
induced (Figs. 4 and 8). The eff  ective induction of Twist2 
in IFNα-treated but not in control macrophages can be 
  explained by specifi  c induction of Twist2 by Axl relative to 
Mer or Tyro 3, or by IFNα-dependent induction of addi-
tional molecules or pathways that regulate Twist2 expression. 
Twist1 and Twist2 have both redundant and unique func-
tions, and diff  erential regulation of the expression of these 
genes would represent one example of divergence in func-
tion between the two genes. Axl ligands are expressed consti-
tutively; for example, the normal serum concentration of 
protein S is  25 μg/ml and apoptotic cells are continuously 
generated in remodeling tissues and in our culture system 
(29, 38). Furthermore, numbers of apoptotic cells increase 
during immune and infl  ammatory reactions, and expression 
of the Gas6 ligand is regulated by many factors, pathways, 
and cytokines, including IFNα itself (unpublished data). 
Thus, the IFN-Axl–mediated homeostatic mechanism is po-
tentiated not only by increased Axl expression but also by in-
creased expression of Axl ligands.
The tissue-specifi   c expression pattern of Axl expres-
sion suggests that IFN induction of Twist and concomitant 
suppression of TNFα production occurs preferentially in 
cells that express Axl, such as myeloid cells. Indeed, IFNα 
did not induce Twist expression in nonmyeloid cell lines 
that were tested (unpublished data). Suppression of TNFα 
production in myeloid cells by Tyro 3 family kinases and 
their immunosuppressive and antiinfl  ammatory  properties 
are well established (24–26), and several signaling pathways 
activated downstream of these kinases have been identifi  ed 
(39–41). However, signaling pathways downstream of Tyro 3 
family kinases that mediate inhibition of infl  ammation are 
not known. Tyro 3 kinases contain a variant immuno-
receptor tyrosine-based inhibitory motif in their cytoplasmic 
domains, and it has been proposed that this immunorecep-
tor tyrosine-based inhibitory motif–like motif may mediate 
a suppressive signal by recruiting SH2-containing protein ty-
rosine phosphatases to these receptors (23). Our results pro-
vide a mechanism by which Tyro 3 family receptors suppress 
macrophage infl  ammatory function, namely, the induction 
of Twist proteins that suppress NF-κB–dependent TNFα 
gene activation.
Twist expression can be induced by NF-κB, and it has 
been previously shown that Twist participates in a negative 
feedback loop in which Twist expression is activated by in-
fl  ammatory factors via activation of NF-κB (22). Twist, in 
turn, binds to E boxes present in the promoters of several 
NF-κB–dependent infl  ammatory cytokines, such as TNFα, 
IL-1, and IL-6, and suppresses cytokine production by block-
ing NF-κB–dependent transcriptional activation (22). The 
induction of Twist by noninfl  ammatory factors, such as Tyro 3 
kinases, establishes that Twist functions not only in feedback 
inhibition but also in negative crossregulation of TNFα ex-
pression by antiinfl  ammatory pathways. Induction of Twist 
by the sequential action of IFNα and Axl results in the bind-
ing of Twist to the TNFα promoter (Fig. 6), where it is 
poised to suppress TNFα expression when cells and NF-κB 
are subsequently activated by FcγR ligation. Similar to NF-
κB–induced Twist, IFNα-induced Twist likely binds to E 
Figure 8.  IFN𝗂 inhibits TNF𝗂 production by induction of Axl and 
Twist. IFNα induces expression of the Tyro 3 family receptor tyrosine 
kinase Axl. Axl, in turn, is activated by Gas6, protein S, and apoptotic cells. 
Protein S is present at high levels in serum, Gas6 can be induced by IFNα, 
and apoptotic cells bind Gas6 and protein S. Axl activation leads to ex-
pression of Twist, which binds to the E box in the TNFα promoter and 
inhibits NF-κB–dependent transcription.JEM VOL. 203, August 7, 2006  1899
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boxes present in the promoters of several genes other than 
TNFα, including infl  ammatory cytokines such as IL-1 and 
IL-8, and thus may more broadly inhibit NF-κB–dependent 
transcription. This prediction is supported by results that pre-
treatment with IFNα suppressed FcγR-mediated induction 
of several cytokine and chemokine genes (Fig. 2). In addi-
tion, IFNα suppressed induction of cytokine expression by 
TLR2 and TLR4, suggesting a more broad role in the in-
hibition of NF-κB–dependent cytokine expression. Further 
work will be required to explain the weaker inhibition of 
TLR4 relative to FcγRs and TLR2. The relative resistance 
of TLR4 to inhibition, even when low concentrations of 
LPS were used, suggests that TLR4 may activate an addi-
tional signaling pathway, such as the Trif-dependent path-
way, that overrides Twist-dependent inhibitory mechanisms. 
Twist also interacts with and modulates the function of sev-
eral other transcription factors expressed in macrophages, in-
cluding bHLH E proteins, MEF2, Runx, and SREBP1 
(42–45), and therefore has the potential to broadly regulate 
the primed macrophage phenotype beyond the inhibition of 
NF-κB responses.
MATERIALS AND METHODS
Cell culture, animals, and reagents. Human macrophages were de-
rived from CD14+ blood monocytes cultured with 10 ng/ml of M-CSF 
(Peprotech). CD14+ monocytes were purifi   ed from peripheral blood 
mononuclear cells obtained from disease-free volunteers using anti-CD14 
magnetic beads (Miltenyi Biotec) as previously described (39). Purity of 
monocytes was >97% as verifi  ed by FACS. Murine bone marrow–derived 
macrophages were obtained as described (39) and maintained in media 
containing 10 ng/ml of M-CSF. Macrophage cells were cultured in RPMI 
1640 medium (GIBCO BRL) supplemented with 10% fetal bovine serum 
(Hyclone). The generation of Twist- and Axl-defi  cient mice has been 
previously described (22, 26). The experiments using human and murine 
cells were approved by, respectively, the Hospital for Special Surgery 
Institutional Review Board and Institutional Animal Care and Use Com-
mittee. Human IFN-α and mouse IFN-α were purchased from Roche 
Applied Science and Peprotech, respectively. IFN-αA/D, a universal 
mammalian type I IFN, was from R&D Systems. Human and mouse IgG 
were from Sigma-Aldrich, human protein S was from Enzyme Research 
Laboratories, and Gas6 was purifi  ed from 293T cells transfected with a 
Gas6 expression plasmid.
ELISA and fl  ow cytometry. Paired TNFα and IL-6 capture and detec-
tion antibodies were purchased from R&D Systems and used in a sandwich 
ELISA according to the instructions of the manufacturer. Murine TNFα 
ELISA was performed by using BD OptEIA ELISA set for mouse TNFα 
from BD Biosciences. Staining for cell surface expression of FcγRs, FcγRI 
(CD64), FcγRII (CD32), and FcγRIII (CD16) was performed using mono-
clonal anti–human CD64, CD32, and CD16 (BD Biosciences). A FACScan 
fl  ow cytometer with CELLQuest software (Becton Dickinson) were used as 
previously described.
mRNA expression analysis. For real-time PCR, total RNA was extracted 
using a RNeasy Mini kit (Qiagen), and 1 μg of total RNA was reverse tran-
scribed using a First Strand cDNA Synthesis kit (Fermentas). Real-time, 
quantitative PCR was performed using iQ SYBR-Green Supermix and 
iCycler iQ thermal cycler (Bio-Rad Laboratories) following the manufacturer’s 
protocols. Relative expression was normalized for levels of GAPDH. The 
generation of only the correct size amplifi  cation products was confi  rmed 
  using agarose gel electrophoresis.
Immunoblotting. Whole cell extracts were obtained, and 10 μg of cell ly-
sates were analyzed by immunoblotting as described (39). Polyclonal rabbit 
anti-Twist2 antibodies were generated (unpublished data) and used as previ-
ously described (22). Monoclonal antibodies against Stat3 and IκBα were 
from BD Transduction Laboratories and Cell Signaling Technology, respec-
tively. Phosphorylation-specifi  c antibodies against Erk (p44/42) and IκBα 
(Ser32) were from Cell Signaling Technology, and antibodies against Erk2 
were from Santa Cruz Biotechnology, Inc.
Electrophoretic mobility shift assay. Electrophoretic mobility shift 
  assays were performed essentially as described (22) using either a TNFα 
promoter fragment that contains an E box (CACATG) that lies 122 bp 
  upstream of the transcription initiation site, or an oligonucleotide contain-
ing a consensus E box (5′-C  C  C  C  A  A  C  A  C  C  T  G  C  C  T  G  C  C  T  G  A  -3′). 5 or 
10 μg of nuclear extract were incubated for 20 min at room temperature 
in a 15-μl binding reaction with 2 ng radiolabeled oligonucleotide and 1 μg 
poly(dI-dC) (GE Healthcare) in binding buff  er containing 20 mM HEPES 
(pH 7.9), 60 mM KCl, 1 mM MgCl2, 0.5 mM DTT, and 10% glycerol. 
For elecrophoresis, 5% polyacrylamide (30:1) gels containing 0.5 × Tris-
borate-EDTA (TBE) with 2.5% glycerol were prerun at 100 V for 2 h at 
4°C in 0.5 × TBE buff  er with 2.5% glycerol. Samples were then loaded 
and gels were run at 4°C in 0.5 × TBE buff  er. For supershift experiments, 
nuclear extracts were incubated with 2 μg Twist or control antibodies 
(Santa Cruz Biotechnology, Inc.) for 20 min at 4°C before the addition of 
radiolabeled oligonucleotide.
Cell transfections. Luciferase reporter constructs containing a 1.3-kb frag-
ment of the TNFα promoter (−1163 to +125 relative to transcription ini-
tiation site) (22) were used. A reporter construct mutated in two out of the 
three E box sequences present in this promoter fragment was generated us-
ing the Quickchange site directed mutagenesis kit (Stratagene); the muta-
tions introduced were −498CACTTG → CCATAC and −122CACATG → 
CTCCAG. RAW267.4 macrophage cells were transfected in duplicate in 
60-mm tissue culture dishes using Eff  ectene (Qiagen) and a total of 2 or 
4 μg plasmid DNA per dish according to manufacturer’s instructions. Cells 
were cotransfected with luciferase reporter constructs, expression plasmids 
encoding Twist1, Twist2, or an empty control expression vector, and a Re-
nilla luciferase-encoding internal control plasmid. 2 d after transfection, cells 
were stimulated by FcγR ligation for 4 h and luciferase activity was mea-
sured and normalized relative to the Renilla luciferase internal control. 
Representative experiments out of fi  ve (wild-type reporter) or four (mutated 
reporter) are shown.
ChIP assay. ChIP assay was performed using a ChIP kit (17–295; Up-
state) according to the manufacturer’s instructions using a polyclonal anti-
Twist rabbit polyclonal antibody (Santa Cruz Biotechnology, Inc.) as 
previously described (22). In brief, 107 primary macrophages were used per 
condition to prepare soluble chromatin which was then immunoprecipi-
tated with either Twist or control (anti-Stat1) antibodies. Extracted DNA 
was amplifi  ed by PCR using primer pairs specifi  c for the E box of the 
TNFα gene promoter (5′-G  G  G  A  G  C  T  A  T  T  T  C  C  A  A  G  A  T  G  T  T  C  T  G  G-
A  G  -3′ and 5′-G  G  G  T  T  T  C  A  G  T  T  C  T  C  A  G  G  G  T  C  C  T  A  T  A  C  A  -3′) or the 
GAS site of the IRF-1 gene promoter (5′-C  T  T  C  G  C  C  G  C  T  A  G  C  T  C  T  A  C-
A  A  C  A  G  -3′ and 5′-G  C  T  C  C  G  G  T  G  G  C  C  T  C  G  G  T  T  C  G  -3′) as previously 
described (22).
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